Elicio Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Elicio Therapeutics Depreciation & Amortization Growth & History (ELTX)
Elicio Therapeutics's depreciation and amortization was $204,000 for fiscal 2025.
View full Elicio Therapeutics company overviewElicio Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $204,000 | −$117,000 | −36.45% |
| 2024 | 2024-12-31 | $321,000 | −$61,000 | −15.97% |
| 2023 | 2023-12-31 | $382,000 | −$8,000 | −2.05% |
| 2022 | 2022-12-31 | $390,000 | $299,000 | +328.57% |
| 2021 | 2021-12-31 | $91,000 | −$7,000 | −7.14% |
| 2020 | 2020-12-31 | $98,000 | — | — |
Elicio Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $100,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $46,000 | −$7,000 | −13.21% |
| Q4 2025 | 2025-12-31 | $286,000 | — | — |
| Q3 2025 | 2025-09-30 | $100,000 | $100,000 | — |
| Q2 2025 | 2025-06-30 | $100,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $53,000 | −$29,000 | −35.37% |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $100,000 | −$4,000 | −3.85% |
| Q1 2024 | 2024-03-31 | $82,000 | −$28,000 | −25.45% |
| Q3 2023 | 2023-09-30 | $0 | −$100,000 | — |
| Q2 2023 | 2023-06-30 | $104,000 | −$50,000 | −32.47% |
| Q1 2023 | 2023-03-31 | $110,000 | $78,000 | +243.75% |
| Q3 2022 | 2022-09-30 | $100,000 | $77,000 | +334.78% |
| Q2 2022 | 2022-06-30 | $154,000 | $131,000 | +569.57% |
| Q1 2022 | 2022-03-31 | $32,000 | $26,000 | +433.33% |
| Q3 2021 | 2021-09-30 | $23,000 | −$24,000 | −51.06% |
| Q2 2021 | 2021-06-30 | $23,000 | −$24,000 | −51.06% |
| Q1 2021 | 2021-03-31 | $6,000 | −$21,000 | −77.78% |
| Q3 2020 | 2020-09-30 | $47,000 | — | — |
| Q2 2020 | 2020-06-30 | $47,000 | — | — |
| Q1 2020 | 2020-03-31 | $27,000 | — | — |
Elicio Therapeutics depreciation and amortization trends
Over the last five fiscal years, Elicio Therapeutics's depreciation and amortization increased from $98,000 to $204,000, a change of $106,000. The latest reported quarter, Q2 2026, shows $100,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elicio Therapeutics source filings ↗